FDA Recommends Recall of Artificial Eye Ointment for Potential Bacterial Contamination
This warning is the second on top of a previous warning not to purchase or use EzriCare Artificial Tears or Delsam Pharma’s Artificial Tears due to potential bacterial contamination.
FDA is warning consumers and health care professionals of the use of Delsam Pharma’s Artificial Eye Ointment because of potential bacterial contamination. This warning is the second on top of a previous warning not to purchase or use EzriCare Artificial Tears or Delsam Pharma’s Artificial Tears due to potential bacterial contamination.
These over-the-counter products are manufactured by Global Pharma Healthcare Private Limited and are intended to be sterile. The use of the ointment can increase the risk of eye infections that can result in blindness according to FDA, and patients who have signs or symptoms of an eye infection should talk to their health care provider or seek medical care immediately warns the agency. FDA recommended that Global Pharma recall Delsam Pharma’s Artificial Eye Ointment on February 22, 2023.
Source: FDA
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
